Topoisomerase I inhibitors and drug resistance

door Parchment, Ralph E., Pessina, Augusto
Gepubliceerd in 1998

ONCOLOGIC PHASE 0 TRIALS INCORPORATING CLINICAL PHARMACODYNAMICS: FROM CONCEPT TO THE PATIENT

door Doroshow, James H., Parchment, Ralph E.
Gepubliceerd in 2008

Pharmacodynamic Endpoints as Clinical Trial Objectives to Answer Important Questions in Oncology Drug Development

door Parchment, Ralph E., Doroshow, James H.
Gepubliceerd in Semin Oncol (2016)

Analyses of the combination of 6-MP and dasatinib in cell culture

door KAUR, GURMEET, BEHRSING, HOLGER, PARCHMENT, RALPH E., MILLIN, MYRTLE DAVIS, TEICHER, BEVERLY A.
Gepubliceerd in 2013

In Vitro Exposure of Precision-Cut Lung Slices to 2-(4-Amino-3-Methylphenyl)-5-Fluorobenzothiazole Lysylamide Dihydrochloride (NSC 710305, Phortress) Increases Inflammatory Cytokin...

door Behrsing, Holger P., Furniss, Michael J., Davis, Myrtle, Tomaszewski, Joseph E., Parchment, Ralph E.
Gepubliceerd in 2013

Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations

door Kinders, Robert, Ferry-Galow, Kate, Wang, Lihua, Srivastava, Apurva K., Ji, Jiuping (Jay), Parchment, Ralph E.
Gepubliceerd in 2014

Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

door Kinders, Robert J., Hollingshead, Melinda, Khin, Sonny, Rubinstein, Larry, Tomaszewski, Joseph E., Doroshow, James H., Parchment, Ralph E.
Gepubliceerd in 2008

Advances in using PARP inhibitors to treat cancer

door Kummar, Shivaani, Chen, Alice, Parchment, Ralph E, Kinders, Robert J, Ji, Jay, Tomaszewski, Joseph E, Doroshow, James H
Gepubliceerd in 2012

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells

door Ji, Jiuping, Kinders, Robert J., Zhang, Yiping, Rubinstein, Larry, Kummar, Shivaani, Parchment, Ralph E., Tomaszewski, Joseph E., Doroshow, James H.
Gepubliceerd in 2011

Effective implementation of novel MET pharmacodynamic assays in translational studies

door Srivastava, Apurva K., Navas, Tony, Herrick, William G., Hollingshead, Melinda G., Bottaro, Donald P., Doroshow, James H., Parchment, Ralph E.
Gepubliceerd in Ann Transl Med (2017)

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

door Sei, Shizuko, Mussio, Jodie K, Yang, Quan-en, Nagashima, Kunio, Parchment, Ralph E, Coffey, Matthew C, Shoemaker, Robert H, Tomaszewski, Joseph E
Gepubliceerd in 2009

The Statistics of Phase 0 Trials

door Rubinstein, Larry V., Steinberg, Seth M., Kummar, Shivaani, Kinders, Robert, Parchment, Ralph E., Murgo, Anthony J., Tomaszewski, Joseph E., Doroshow, James H.
Gepubliceerd in 2010

Validation of a Hypoxia-Inducible Factor-1α Specimen Collection Procedure and Quantitative ELISA in Solid Tumor Tissues

door Park, Sook Ryun, Kinders, Robert J., Khin, Sonny, Hollingshead, Melinda, Antony, Smitha, Parchment, Ralph E., Tomaszewski, Joseph E., Kummar, Shivaani, Doroshow, James H.
Gepubliceerd in Anal Biochem (2014)

Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug—induced DNA double strand breaks from D...

door Dull, Angie B., Wilsker, Deborah, Hollingshead, Melinda, Mazcko, Christina, Annunziata, Christina M., LeBlanc, Amy K., Doroshow, James H., Kinders, Robert J., Parchment, Ralph E.
Gepubliceerd in Oncotarget (2018)

Topoisomerase I Levels in the NCI-60 Cancer Cell line Panel Determined by Validated ELISA and Microarray Analysis and Correlation with Indenoisoquinoline Sensitivity

door Pfister, Thomas D., Reinhold, William, Agama, Keli, Gupta, Shalu, Khin, Sonny A., Kinders, Robert J., Parchment, Ralph E., Tomaszewski, Joseph E., Doroshow, James H., Pommier, Yves
Gepubliceerd in 2009

Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers

door Wilsker, Deborah F., Barrett, Allison M., Dull, Angie B., Lawrence, Scott M., Hollingshead, Melinda, Chen, Alice P., Kummar, Shivaani, Parchment, Ralph E., Doroshow, James H., Kinders, Robert J.
Gepubliceerd in Clin Cancer Res (2019)

Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

door Kinders, Robert J., Hollingshead, Melinda, Lawrence, Scott, Ji, Jiuping, Tabb, Brian, Bonner, William M., Pommier, Yves, Rubinstein, Larry, Evrard, Yvonne A., Parchment, Ralph E., Tomaszewski, Joseph, Doroshow, James H.
Gepubliceerd in 2010

Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

door Wang, Lihua H., Pfister, Thomas D., Parchment, Ralph E., Kummar, Shivaani, Rubinstein, Larry, Evrard, Yvonne A., Gutierrez, Martin E., Murgo, Anthony J., Tomaszewski, Joseph E., Doroshow, James H., Kinders, Robert J.
Gepubliceerd in 2010

Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream(®) system

door Balasubramanian, Priya, Kinders, Robert J., Kummar, Shivaani, Gupta, Vishal, Hasegawa, David, Menachery, Anoop, Lawrence, Scott M., Wang, Lihua, Ferry-Galow, Katherine, Davis, Darren, Parchment, Ralph E., Tomaszewski, Joseph E., Doroshow, James H.
Gepubliceerd in PLoS One (2017)

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

door Srivastava, Apurva K., Hollingshead, Melinda G., Govindharajulu, Jeevan P., Covey, Joseph M., Liston, Dane, Simpson, Melanie A., Peggins, James O., Bottaro, Donald P., Wright, John J., Kinders, Robert J., Doroshow, James H., Parchment, Ralph E.
Gepubliceerd in Mol Cancer Ther (2018)